Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

2.3K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.3K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

496
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
496
Analgesia and Pain Management01:25

Analgesia and Pain Management

911
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
911
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

443
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
443
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

369
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
369
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

3.1K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.

International journal of molecular sciences·2026
Same author

The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.

International journal of molecular sciences·2025
Same author

Respiratory and Cardiovascular Activity of LENART01, an Analgesic Dermorphin-Ranatensin Hybrid Peptide, in Anesthetized Rats.

International journal of molecular sciences·2025
Same author

Impaired Breathing During Exposure to Hypoxia and Carotid Body Dysfunction in an Animal Model of Parkinson's Disease.

Comprehensive Physiology·2025
Same author

Molecular Hydrogen in the Treatment of Respiratory Diseases.

International journal of molecular sciences·2025
Same author

A Novel Tetrahydroacridine Derivative with Potent Acetylcholinesterase Inhibitory Properties and Dissociative Capability against Aβ42 Fibrils Confirmed by In Vitro Studies.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Oct 9, 2025

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.4K

Non-Opioid Peptides Targeting Opioid Effects.

Katarzyna Kaczyńska1, Piotr Wojciechowski1

  • 1Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawińskiego 5 St., 02-106 Warsaw, Poland.

International Journal of Molecular Sciences
|December 24, 2021
PubMed
Summary

Researchers are exploring peptides to counteract opioid side effects like addiction and respiratory depression. These compounds show potential in modulating opioid actions, offering safer pain management strategies.

Keywords:
antinociceptionnon-opioid peptidesopioid side effectsrespiratory depressiontolerance

More Related Videos

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

21.3K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.5K

Related Experiment Videos

Last Updated: Oct 9, 2025

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.4K
Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

21.3K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.5K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pain Management

Background:

  • Opioids are potent analgesics used widely, especially in palliative care.
  • Opioid use is linked to significant side effects including tolerance, addiction, respiratory depression, and cardiovascular events.
  • These side effects necessitate strategies to mitigate opioid-related risks and improve patient safety.

Purpose of the Study:

  • To review recent findings on peptides that modulate opioid actions.
  • To explore the potential of various peptides in counteracting opioid side effects.
  • To focus on peptides influencing cardiovascular and respiratory responses to opioids.

Main Methods:

  • Literature review of scientific articles on peptide-opioid interactions.
  • Analysis of studies investigating pro- and anti-opioid activities of selected peptides.
  • Compilation of data on peptides affecting opioid-related cardiovascular and respiratory effects.

Main Results:

  • Several peptides, including neuropeptide FF (NPFF), cholecystokinin (CCK), and melanocyte inhibiting factor (MIF), exhibit modulatory effects on opioids.
  • Other peptides like nociceptin/orphanin (N/OFQ), ghrelin, oxytocin, endothelin, and venom peptides also demonstrate significant opioid-modulating properties.
  • These peptides influence opioid actions, potentially offering ways to manage side effects.

Conclusions:

  • Peptides represent a promising avenue for developing strategies to counteract opioid side effects.
  • Further research into peptide-opioid interactions could lead to safer and more effective pain management.
  • Targeting peptide pathways may offer novel therapeutic approaches for opioid-associated complications.